CytoSorbents, Inc.

CytoSorbents, Inc. is a medical technology company specializing in hemoadsorption blood purification therapy. The company develops extracorporeal adsorption devices based on proprietary biocompatible polymer bead technology designed to reduce elevated levels of potentially harmful compounds from whole blood. The primary product, CytoSorb 300®, is an adsorber that complements conventional dialysis approaches and is used in critical care, cardiovascular, liver, and kidney therapeutic areas. CytoSorbents also offers PuriFi, an independent therapy platform enabling standalone CytoSorb® use; ECOS-300CY for ex vivo organ perfusion applications; and VetResQ for veterinary critical-care applications. The company maintains a global presence in over 75 countries and provides clinical support through a team of specialists. Products are CE-marked and available internationally, though CytoSorb 300® and related human therapeutics are not authorized or cleared in the US market. VetResQ is available only in the US. The company positions itself as a trusted partner for advanced blood purification technologies in settings where physiological balance and management of inflammatory or harmful substances is critical.